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Tuberculosis (TB) is a global public health problem with an estimated 9.6 million incident cases in 2014, of which 480,000 were cases of multidrug-resistant TB (MDR-TB) ([@B1]). In 2014, TB caused about 1.5 million deaths worldwide. Extensively drug-resistant TB (XDR-TB) has been reported by 105 countries to date, and an estimated 9.7% of patients with MDR-TB have XDR-TB ([@B1]). The continued increase and spread of XDR-TB cases is becoming a serious threat to public health worldwide, underscoring the need for better clinical management and development of new drugs ([@B1][@B2]).

The TB Latin American--Mediterranean (LAM) sublineage belongs to lineage 4, Euro-American, one of the seven major phylogeographical *Mycobacterium tuberculosis* lineages that have been described around the world ([@B3][@B4]). Although it has been reported with considerable variation among countries, LAM is predominant in Latin America ([@B5][@B6][@B7]). To better understand the molecular mechanisms involved in the extensive drug resistance of *M. tuberculosis* strains from the LAM sublineage, we sequenced the whole genome of two clinical isolates from Medellín, Colombia.

A 24-locus mycobacterial interspersed repetitive-unit--variable-number tandem-repeat (MIRU-VNTR) profile was used to confirm the assignment of isolates TBR-152 and TBR-175 to the *M. tuberculosis* LAM sublineage ([@B8]). Phenotypic susceptibility tests to first- and second-line drugs were performed using the Bactec MGIT 960 method. It was determined that TBR-152 and TBR-175 are resistant to isoniazid, rifampin, ofloxacin, moxifloxacin, and amikacin, classifying them as XDR-TB. Genomic DNA was obtained from both isolates by the cetyl-trimethyl-ammoniumbromide method ([@B9]). Samples were treated with RNase prior to paired-end library construction with an average insert size target of 800 bp. Whole-genome sequencing was performed at the J. Craig Venter Institute (Rockville, Maryland, USA) on an Illumina MiSeq platform with 250-bp reads and to about 70× coverage. The draft whole-genome sequences comprise 4,303,775 bp and 4,330,115 bp for TBR-152 and TBR-175, respectively. Both genomes display 65% GC content, and *N*~50~ contig lengths were 81,320 bp for TBR-152 and 67,246 bp for TBR-175. A *de novo* assembly was carried out using Celera Assembler (PMID: 18321888), and structural and functional annotation was completed using multiple-ranked sources of evidence, including the TIGRFAMs (PMID: 23197656) and Pfam (PMID: 24288371) protein family databases. The assemblies contain 4,398 and 4,415 protein-coding genes for TBR-152 and TBR-175, respectively, along with 45 tRNAs for each isolate. Mutations associated with resistance to rifampin (S450L in *rpoB*) and isoniazid (S315T in *katG*) were encountered in both genomes. Also, TBR-152 displayed the *rrs* gene A1401G substitution associated with resistance to aminoglycosides, as well as the *gyrA* S91P mutation associated with resistance to fluoroquinolones. Interestingly, TBR-175 displayed no mutation associated with resistance to either fluoroquinolones or aminoglycosides.

This report on LAM sublineage XDR-TB Colombian isolates will provide material for comparative genomic analysis with other XDR-TB genomes circulating in Latin America and in other regions of the world ([@B10][@B11][@B14]).
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These genome projects have been deposited at DDBJ/EMBL/GenBank under the accession numbers [JRJQ00000000](JRJQ00000000) for TBR-152 and [JRJR00000000](JRJR00000000) for TBR-175. The versions described in this paper are the first versions, JRJQ01000000 and JRJR01000000.
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